For research use only
| Cat No. | ABC-SC0136 |
| Product Type | Human Cancer Stem Cells |
| Cell Type | Stem Cell |
| Species | Human |
| Growth Conditions | 37 ℃, 5% CO2 |
| Source Organ | Breast |
| Disease | Breast Cancer |
| Storage | Liquid Nitrogen |
Human breast cancer stem cells possess tumorigenic, drug-resistant traits and multilineage potential, ideal for studying TNBC initiation and therapy.
HighQC™ Human (Parental) Breast Cancer Stem Cells are derived from human breast carcinoma tissue and represent a subpopulation of tumor-initiating cells with stem-like properties. These cells exhibit an epithelial morphology and express characteristic markers such as CD44 and CD133.Maintained under serum-free, non-adherent culture conditions, they maintain self-renewal capacity and can recapitulate tumor heterogeneity upon differentiation. Karyotype analysis often reveals chromosomal instability. Morphologically, the cells appear as compact, round-to-oval clusters with a high nuclear-to-cytoplasmic ratio, consistent with an undifferentiated state. Gene expression profiling reveals upregulation of stemness-associated genes such as NANOG, SOX2, and OCT4. They are ideal for studying the molecular pathways underlying breast cancer initiation, progression, metastasis, and resistance to therapy.
| Product Code | HighQC™ Human (Parental) Breast Cancer Stem Cell, Human Parental Breast CSC, hPara-BCSC, Human Breast Cancer Progenitors |
| Species | Human |
| Cat.No | ABC-SC0136 |
| Product Category | Stem Cells |
| Size/Quantity | 1 vial |
| Cell Type | Stem Cell |
| Growth Mode | Adherent |
| Shipping Info | Dry Ice |
| Growth Conditions | 37 ℃, 5% CO2 |
| Source Organ | Breast |
| Disease | Breast Cancer |
| Biosafety Level | 1 |
| Storage | Liquid Nitrogen |
| Product Type | Human Cancer Stem Cells |
HighQC™ Human (Parental) Breast Cancer Stem Cells serve as a powerful model for studying drug resistance mechanisms and developing targeted therapies against cancer stem cells, which are the major focus in breast cancer treatment. Additionally, they support research on tumor heterogeneity, EMT processes, and biomarker validation. These cells are also suitable for high-throughput drug screening, transcriptomic analysis, and PDX model establishment, making them a versatile platform for advancing breast cancer research.
When you publish your research, please cite our product as "AcceGen Biotech Cat.# XXX-0000". In return, we’ll give you a $200 coupon. Simply click here and submit your paper’s PubMed ID (PMID).